Your body makes zombie cells on purpose. That is the part most articles skip.
When a cell accumulates enough DNA damage that dividing again would be dangerous, it shuts down its own division machinery, permanently. That is cellular senescence, and it is an anti-cancer mechanism. The failure comes afterwards. The cell does not leave. It settles into the tissue and starts signalling.
What it signals is the actual problem. Senescent cells secrete a mix of inflammatory proteins and matrix-degrading enzymes into the space around them, and there is reasonable evidence that not all of that signal stays local. I gave a TEDx talk called “How Sunburns and Zombie Cells Affect Your Health” because that second half is the part patients have never been told.
Key Takeaways
– Zombie cells are senescent cells: damaged cells that stop dividing but resist the normal death signal and accumulate in tissue with age and sun exposure.
– Their secretions, collectively the SASP, break down collagen, suppress immune surveillance, and feed chronic low-grade inflammation.
– The idea that senescent skin cells influence distant tissue is biologically coherent and supported by animal work. It is not proven as a causal chain in humans.
– Human senolytic evidence is small, early and mostly open-label. The most publicised supplement result to date is a single-arm study run by the company selling the product.
– Senolytics do not clear every senescent cell. A resistant population survives treatment, which is why a new class of “senosensitizers” is being developed (Aging Cell).
What are zombie cells, and why does your body make them?
Zombie cells are senescent cells. When UV exposure, oxidative stress or telomere shortening damages a cell past the point of safe repair, the cell enters permanent cell-cycle arrest rather than risk becoming cancerous. That arrest is protective. The problem is that these cells then resist apoptosis, the normal programmed death pathway, and persist.
So you end up with a cell that cannot do its job and will not leave.
In skin, ultraviolet radiation is the dominant driver. A 2021 review in the Journal of Investigative Dermatology by Fitsiou and colleagues positions cellular senescence and its secretory phenotype as central mechanisms of skin photoaging, not incidental findings alongside it. Every meaningful sunburn adds to that pool. The cells do not all clear, and the pool does not shrink on its own.
This is worth being precise about, because the popular framing gets it backwards. Senescence is not a malfunction. The malfunction is clearance. A young immune system finds and removes senescent cells reasonably well. An older one does not keep up, so the burden builds at the same time the removal system is weakening.
What does the SASP actually do to your tissue?
The SASP, or senescence-associated secretory phenotype, is the set of molecules a senescent cell releases: inflammatory cytokines such as IL-6, IL-8, IL-1 beta and TNF-alpha, chemokines, growth factors, and matrix metalloproteinases. Ghosh and Capell described it in 2016 as a critical effector in both skin aging and skin cancer, which is the uncomfortable part.
A single senescent cell is not a problem. A field of them, all broadcasting, changes the behaviour of the tissue they sit in.
| What the SASP does | Mechanism | What you notice |
|---|---|---|
| Degrades the matrix | Matrix metalloproteinases break down collagen and elastin | Laxity, lines, thinner and less resilient skin |
| Drives chronic inflammation | IL-6, IL-8, TNF-alpha sustain a low-grade inflammatory state | Persistent redness, slower healing, “inflammaging” |
| Suppresses immune surveillance | Alters the local immune environment that normally removes abnormal cells | Fewer early abnormal cells cleared before they matter |
| Spreads senescence | Paracrine signalling pushes neighbouring healthy cells into arrest | The affected field grows over time |
Note the paradox in the third and fourth rows. A mechanism that exists to stop one cell from becoming cancerous produces a tissue environment that is friendlier to cancer in the cells around it. Both things are true at once.
This is why I think “anti-aging” is the wrong frame for skin. You are not fighting the passage of time. You are managing an inflammatory signalling problem in a specific tissue, and inflammation is something we can actually measure.
Can a sunburn on your back affect tissue somewhere else?
Possibly, and the mechanism is not what most people assume. The UV mutation itself is local, since photons only damage where they land. What may travel is the inflammatory signalling and the immune suppression that follows. That is a promotion effect, not mutation at a distance, and it is a hypothesis rather than settled human fact.
I want to be direct about the evidence status before going further. The individual links in this chain have support. The full chain, that clearing senescent cells in skin reduces cancer risk in a distant organ, has not been demonstrated in humans.
What the animal work shows
In 1985, Strickland, Creasia and Kripke irradiated the bellies of mice with UVB, then applied a tumour promoter to the backs, which had never been exposed to UV. Tumours developed on those unexposed backs only in the animals whose bellies had been irradiated. UV in one place changed what was possible somewhere else.
The proposed explanation came later from the same laboratory. Kripke and colleagues reported in PNAS in 1992 that pyrimidine dimers, the specific DNA lesions UV creates, initiate systemic immunosuppression in irradiated mice. The damage is local. The immune consequence is not.
More recently, a 2026 paper in Nature Aging by Li and colleagues reported that extracellular vesicles released by senescent liver cells travel through the blood and increase invasiveness and metastasis across several tumour types in aged mice, and that the effect was reversible with senolytic treatment. Aged mice, not people. But it is a clean demonstration that senescent cells in one organ can change behaviour in another.
Separately, Bald and colleagues reported in Nature in 2014 that UV-induced inflammation promotes angiotropism and metastatic behaviour in melanoma in a mouse model. Again, the inflammation is doing work that the mutation alone does not explain.
The chain, stated honestly
- UV creates senescent cells in exposed skin. Well supported.
- Those cells secrete SASP factors and extracellular vesicles. Well supported.
- Some of that signal reaches the circulation. Supported in animal models.
- At distant sites it suppresses immune surveillance and favours a pro-tumour environment. Supported in animal models.
- A pre-existing abnormal cell at that distant site therefore faces less resistance. Plausible, not demonstrated in humans.
Steps one and two are textbook. Step five is where I stop claiming and start saying “this is why I behave the way I do about sun protection.”
Why immune function is the hinge
The strongest indirect argument comes from transplant medicine. Organ transplant recipients on long-term immunosuppression develop skin cancers, particularly squamous cell carcinoma, at rates far above the general population. Wheless and colleagues reviewed this in 2014. Published estimates of the size of that increase vary widely depending on the population studied and the drug regimen, so I will not quote a multiplier. The direction is not in dispute, and the direction is the point.
Those patients are not getting more sun. They have lost the system that patrols for abnormal cells. If removing immune surveillance raises cancer risk that sharply, then immune surveillance is doing real work every day in everyone else, and anything that degrades it, including a sustained SASP burden, is worth taking seriously.
Why this is not an abstract question for me
I had skin cancer in my thirties. Caught early, treated, fine. Then I developed an autoimmune disease, which is my own immune system doing the opposite of ignoring things.
That combination changed the question I was asking. Not “how do we treat this,” which I already knew, but “what was happening inside me that allowed both of these.” The answer I kept arriving at was inflammation, senescent cell burden, and an immune system that was not functioning the way I had assumed it was. None of which anyone was measuring.
So I started measuring. That is most of what changed in how I practise: not a new product, a different sequence. Establish where someone actually is before deciding what to do about it.
Do senolytics actually clear zombie cells in humans?
Not proven. Senolytic drugs clear senescent cells convincingly in mice, with real functional benefits in those animals. Human evidence exists but is small, short, mostly open-label and often without a control group. Anyone telling you senolytics are established therapy for healthy adults is ahead of the data.
The first-in-human work is worth understanding because of how modest it was. Justice and colleagues published an open-label pilot study of dasatinib plus quercetin in patients with idiopathic pulmonary fibrosis in EBioMedicine in 2019. Fourteen patients, no control arm, physical function endpoints. It was a signal that the approach could be tested in people. It was not a demonstration of benefit in healthy adults, and it has been repeatedly described online as something it was not.
Then there is the supplement study that generated the 2026 headlines.
In 2026, Qualia Life Sciences published proteomics data in the International Journal of Molecular Sciences on its own commercial senolytic supplement. Healthy adults aged 45 to 79 took a single two-day course. Four SASP-associated proteins, CCL8, CXCL9, CXCL10 and CXCL11, decreased, and proteins associated with tissue repair increased. That is a real result from a real human study, and it deserves the qualifier the authors themselves used: exploratory.
Here is what the coverage left out. It was a single-arm pilot with no control group and no placebo. The company that sells the product designed and funded the study. The markers moved before statistical adjustment. A company grading its own homework with no answer key is not fraud, but it is not proof either.
| Approach | Where the evidence sits | What is genuinely shown | What is not shown |
|---|---|---|---|
| Dasatinib + quercetin | Small human studies, several trials ongoing | Feasible and tested in people; clear effects in animal models | Benefit in healthy adults; durable outcomes; long-term safety |
| Fisetin | Mostly preclinical, human trials underway | Senolytic activity in cell and animal models | Human clearance of senescent burden at supplement doses |
| Navitoclax | Early-phase clinical work | Potent senolytic activity | A tolerable profile for general use; its effect on platelets is the known limitation |
| Commercial supplement blends | One single-arm manufacturer study | Movement in four SASP-related proteins over two days | That your senescent cell burden changed |
| Senosensitizers | Preclinical only | Concept for making resistant cells vulnerable | Anything in humans |
In our clinic, senolytics are a physician-assessed decision with measurement on both ends, not something I hand out. If you are considering one, that conversation belongs with a doctor who knows your history and your bloodwork, not with a supplement label.
Why can’t senolytics clear all of them?
Because a fraction of senescent cells survives treatment. Work by Tripathi and colleagues published in Aging Cell reports that senolytic agents clear roughly 30 to 70 percent of senescent cells in the models studied, and that the survivors are senolytic-resistant with a distinct SASP profile of their own. They are not inert leftovers.
This matters more than it first appears.
If a course of treatment removes half the population and the remaining half has a different, potentially more damaging secretory profile, then a single course is not a reset. It is a partial edit. That research group’s proposed answer is a new drug class, senosensitizers, designed to make resistant cells vulnerable to senolytics that would otherwise fail on them. Those are preclinical. There is nothing to take.
Individual variation compounds it. Baseline burden, immune competence, genetics and lifestyle all plausibly influence how much of that population a given person clears. Which brings the whole article to the same place it keeps arriving at: the average result in a study is not your result, and the only way to distinguish them is to measure.
Can a laser clear zombie cells from sun-damaged skin?
Partly, and this is the most interesting open question in my field right now. A 2021 randomised controlled trial in 48 people found that fractional laser resurfacing eliminated senescent fibroblasts in aged skin, and that doing so reduced the procarcinogenic UVB response of that skin (Spandau et al., Journal of Clinical Investigation, 2021). Ablative fractional CO2 devices are cleared for skin resurfacing. Using them deliberately as a senescence intervention is a research question, not an established indication.
What we know reasonably well is that ablative fractional resurfacing treats field damage rather than individual lesions, which is a different goal from smoothing texture.
My hypothesis, stated as a hypothesis: if a laser pass removes senescent fibroblasts from a large field of chronically sun-damaged skin, it is plausibly lowering the total SASP output from that field. If the systemic argument above holds, then treating the skin you can see may be doing something for tissue you cannot. I find that reasoning compelling. I also cannot prove it, and nobody has run the trial that would. I tell patients both halves of that sentence.
What I do not do is sell a laser on a cancer-prevention promise. The indication is the skin in front of us. The systemic question stays labelled as a question. For readers who want the treatment detail rather than the biology, our Guelph clinic covers eCO2 laser skin resurfacing separately.
What our own formulation work targets in the skin
Oral senolytics aim to kill senescent cells throughout the body. Our formulation work took the opposite route: reduce the inflammatory output and the oxidative drivers at the skin surface, where UV-induced senescence is concentrated. The platform is GMA7, and it is a topical cosmeceutical, not a drug and not a senolytic.
In translational research we presented with colleagues from UBC, McMaster, Western and Guelph Dermatology Research, GMA7 pre-treatment significantly attenuated the core senescence-associated inflammatory response in UV-exposed human cells:
| Marker | Effect with GMA7 pre-treatment | Model |
|---|---|---|
| IL-6, a core SASP cytokine | Reduced by 94% (p < 0.01) | Keratinocyte and fibroblast co-culture, UV-induced |
| IL-8 (CXCL8) | Reduced by 82% (p < 0.001) | Same model, post-UV exposure |
| Reactive oxygen species | Reduced by 88% (p < 0.01) | Primary human keratinocytes |
| BNIP3, a senescence-associated marker | Significantly attenuated (p < 0.05) | UV-exposed human cells |
Read those numbers for exactly what they are. That is cell culture. Cells in a dish are not a patient, and a percentage reduction in a cytokine is not a clinical outcome. I publish them because the mechanism is specific and testable, not because they predict what your face will do.
The design logic follows the twelve hallmarks of aging framework set out by López-Otín and colleagues in Cell in 2023. Senescence is one hallmark. Inflammation, genomic instability and altered intercellular communication are others, and in photodamaged skin they are all active simultaneously. Formulating against one pathway is not wrong, it is just working one front while the tissue fights on several. That reasoning is also why our Rejuvenat serum pairs the GMA7 complex with DNA-repair enzymes rather than relying on antioxidants alone.
How would you know if any of this is working for you?
You measure before and after, or you are guessing. Whether the intervention is a supplement, a topical, a laser or a lifestyle change, the question is identical: did anything move in your biology. Not the average in a trial. Not the claim on the box. Your numbers, against your own baseline.
Standard bloodwork will not answer it. A lipid panel and a glucose reading say nothing about senescent burden or immune surveillance.
| What we track | Why it is on the list |
|---|---|
| hs-CRP | General systemic inflammatory load |
| IL-6 | A SASP cytokine secreted directly by senescent cells |
| Vitamin D (25-OH) | Deficiency impairs T-cell and NK cell function |
| Immune panel, including NK cell activity | The surveillance system this whole argument depends on |
| Epigenetic age clock | Biological versus chronological age over time |
| Homocysteine | Methylation status, relevant to DNA repair capacity |
| Multi-spectral skin imaging | Quantifies UV damage and sub-surface inflammation you cannot see |
| Barrier and elasticity measurement | Tissue function rather than appearance |
| Skin antioxidant capacity (PAOT) | In-vivo reserve against oxidative drivers of senescence |
The pattern I see most often is not a dramatic abnormality. It is someone whose inflammatory markers have been drifting upward for years while every routine result came back “normal,” because nothing on the routine panel was looking at inflammation. Seeing that trend line is what changes behaviour, far more reliably than being told to wear sunscreen.
None of these are tests to order for yourself off a menu. We select them against a specific clinical question and interpret them in context. Talk to your own physician before acting on anything here, particularly if you take prescription medication.
What a layered strategy looks like
Since no single agent clears the whole senescent population, the rational approach is layered: prevent new senescence, reduce the damage from what is already there, remove what can be removed, and measure whether any of it worked.
| Layer | What it does | Evidence status |
|---|---|---|
| Sun protection | Prevents new UV-driven senescence. The cheapest intervention here by a distance | Well established |
| Topical senescence-targeted actives | Reduce SASP signalling and oxidative load at the surface | Mechanistic and preclinical, including our own |
| Ablative fractional laser | Treats field damage; shown in a human RCT to eliminate senescent fibroblasts | Published human mechanism, systemic benefit unproven |
| Sleep, exercise, nutrition, stress | Support immune surveillance and lower inflammatory tone | Strong general evidence, no senescence-specific numbers I would quote |
| Oral senolytics | Aim to clear senescent cells systemically | Early, physician-assessed only |
| Longitudinal measurement | Tells you which of the above did anything | The step that makes the rest interpretable |
If I had to rank them by honest confidence, sun protection and sleep sit above every product on the list, including mine. That is not modesty. It is what the evidence supports.
Frequently asked questions
What exactly are zombie cells?
Zombie cells are senescent cells: cells that have stopped dividing because of accumulated damage but resist apoptosis and remain in the tissue. They secrete the SASP, a mix of inflammatory cytokines, chemokines and matrix-degrading enzymes that damages surrounding tissue, degrades collagen and alters local immune function.
Can a sunburn on my back really affect tissue somewhere distant?
The mutation stays local, since UV only damages where it lands. The inflammatory signalling can travel. Animal studies going back to 1985 show UV at one site promoting tumour development at unexposed sites through immune suppression. In humans this remains a coherent hypothesis, not a demonstrated causal chain.
Should I take a senolytic supplement right now?
That is a decision for you and your physician, not an article. What I would say is that the human evidence is early, the best-publicised supplement study was single-arm and run by the manufacturer, and a two-day course is unlikely to clear an entire senescent population. Baseline measurement first makes the question answerable.
Why can’t senolytics clear every senescent cell?
Research published in Aging Cell reports that senolytics clear roughly 30 to 70 percent of senescent cells in the models studied, and that the survivors are resistant with a distinct secretory profile. A drug class called senosensitizers is being developed to make those resistant cells vulnerable, but that work is preclinical.
Does CO2 laser clear senescent cells?
A 2021 randomised controlled trial in 48 people found that fractional laser resurfacing eliminated senescent fibroblasts in aged skin and reduced that skin’s procarcinogenic UVB response. These devices are cleared for skin resurfacing, so using them specifically as a senescence intervention is an area of active research rather than an established indication.
Is GMA7 a senolytic?
No. GMA7 is a topical cosmeceutical platform that targets senescence-associated signalling in skin. Senolytics aim to kill senescent cells. Our work aims to reduce the inflammatory and oxidative output around them and limit new UV-driven senescence. The approaches address different points in the same process.
Where this leaves you
Cellular senescence is one of the better-characterised mechanisms in aging biology. The interventions aimed at it are not at the same stage, and the gap between those two statements is where most of the marketing lives.
What I am confident about: senescent cells accumulate, their secretions damage tissue, UV is the main driver in skin, and immune surveillance matters enormously. What I am not confident about: that any currently available senolytic meaningfully clears your burden, or that clearing skin senescence changes what happens elsewhere in your body. I would like both of those to be true. Wanting them is not evidence.
So the sequence I would follow is unglamorous. Protect the skin. Support the immune system. Establish where you actually stand with real measurements. Then, and only then, decide whether an intervention is worth adding, and measure again to find out whether it did anything.
If you want to know your own baseline before you buy anything, that assessment is the place to start. Book a consultation.
Sources
- Strickland PT, Creasia D, Kripke ML. “Enhancement of two-stage skin carcinogenesis by exposure of distant skin to UV radiation.” Journal of the National Cancer Institute, 1985;74(5):1129-1134. Retrieved 2026-09-22. https://doi.org/10.1093/jnci/74.5.1129
- Kripke ML, Cox PA, Alas LG, Yarosh DB. “Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice.” PNAS, 1992;89(16):7516-7520. Retrieved 2026-09-22. https://doi.org/10.1073/pnas.89.16.7516
- Li H, Zhao R, Wan L, et al. “Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging.” Nature Aging, 2026. Mouse model. (DOI pending verification.)
- Bald T, Quast T, Landsberg J, et al. “Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.” Nature, 2014;507:109-113. Mouse model. Retrieved 2026-09-22. https://doi.org/10.1038/nature13111
- Tripathi U, et al. “Senolytic-Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers.” Aging Cell, 2025. Retrieved 2026-09-22. https://doi.org/10.1111/acel.70358
- Justice JN, et al. “Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study.” EBioMedicine, 2019;40:554-563. Open-label, n=14, no control arm. Retrieved 2026-09-22. https://doi.org/10.1016/j.ebiom.2018.12.052
- Blomquist et al. “Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers.” International Journal of Molecular Sciences, 2026;27(10):4406. Single-arm, manufacturer-funded and manufacturer-authored. Trial registration NCT06953518. Retrieved 2026-09-22. https://doi.org/10.3390/ijms27104406
- Fitsiou E, Pulido T, Campisi J, Alimirah F, Demaria M. “Cellular Senescence and the Senescence-Associated Secretory Phenotype as Drivers of Skin Photoaging.” Journal of Investigative Dermatology, 2021;141(4S):1119-1126. Retrieved 2026-09-22. https://doi.org/10.1016/j.jid.2020.09.031
- Ghosh K, Capell BC. “The Senescence-Associated Secretory Phenotype: Critical Effector in Skin Cancer and Aging.” Journal of Investigative Dermatology, 2016;136(11):2133-2139. Retrieved 2026-09-22. https://doi.org/10.1016/j.jid.2016.06.621
- Wheless L, et al. “Skin cancer in organ transplant recipients: more than just sun.” 2014. (Journal title, volume and DOI pending verification.)
- Spandau DF, Chen R, et al. “Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia.” Journal of Clinical Investigation, 2021;131(19):e150972. Randomised controlled trial, n=48. Retrieved 2026-09-22. https://doi.org/10.1172/JCI150972
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. “Hallmarks of aging: An expanding universe.” Cell, 2023;186(2):243-278. Retrieved 2026-09-22. https://doi.org/10.1016/j.cell.2022.11.001
- Sareen K, Sajic D, et al. “Addressing the Field, Not Just the Lesion: A Translational Study of Skin Quality and Actinic Keratoses Improvement.” Conference proceedings. Author’s own research.